Surgalign Holdings (OTCPK:SRGA.Q) - Aktienkurs, Nachrichten und Analyse

SRGA.Q Aktienübersicht

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide.

Über das Unternehmen

SRGA.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 9.6% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung ($165K)

Negatives Eigenkapital

Stark schwankender Aktienkurs in den letzten 3 Monaten

+ 2 mehr Risiken

Surgalign Holdings, Inc. Wettbewerber

Procyon

OTCPK:PCYN

US$2.2m

InVitro International

OTCPK:IVRO

US$2.0m

Vycor Medical

OTCPK:VYCO

US$2.6m

Wearable Health Solutions

OTCPK:WHSI

US$182.7k

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Surgalign Holdings
Historische Aktienkurse
Aktueller Aktienkurs	US$0.018
52-Wochen-Hoch	US$4.00
52-Wochen-Tief	US$0.005
Beta	1.49
11 Monat Veränderung	63.64%
3 Monate Veränderung	-80.00%
1 Jahr Veränderung	-99.50%
33 Jahre Veränderung	-99.97%
5 Jahre Veränderung	-99.99%
Veränderung seit IPO	-100.00%

Aktuelle Nachrichten und Updates

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Aktionärsrenditen

	SRGA.Q	US Medical Equipment	US Markt
7D	16.1%	-1.1%	0.6%
1Y	-99.5%	19.7%	32.1%

Rendite im Vergleich zur Industrie: SRGA.Q unter dem Niveau der Branche US Medical Equipment, die im vergangenen Jahr eine Rendite von 5.5% erzielte.

Rendite vs. Markt: SRGA.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	8.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: SRGA.QDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: SRGA.QDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 28% auf 40% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Surgalign Holdings im Vergleich zum Marktanteil des Unternehmens?
SRGA.Q grundlegende Statistiken
Marktanteil	US$165.30k
Gewinn(TTM)	-US$50.49m
Umsatz(TTM)	US$78.12m

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist SRGA.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SRGA.Q Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$78.12m
Kosten der Einnahmen	US$26.03m
Bruttogewinn	US$52.09m
Sonstige Ausgaben	US$102.58m
Umsatz	-US$50.49m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-5.50
Bruttomarge	66.68%
Nettogewinnspanne	-64.63%
Schulden/Eigenkapital-Verhältnis	-54.1%

Wie hat sich SRGA.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

SRGA.Q Aktienübersicht

Belohnungen

Risikoanalyse

Surgalign Holdings, Inc. Wettbewerber

OTCPK:PCYN

US$2.2m

OTCPK:IVRO

US$2.0m

OTCPK:VYCO

US$2.6m

OTCPK:WHSI

US$182.7k

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Erträge & Einnahmen